Independent · Source-linked · Human-verified

What's the legal status, today?

“Legal” is rarely a clean yes or no - so we don't pretend it is. Peptlas is a neutral, independent reference that tracks the U.S. and international regulatory status of named compounds under FDA process - every entry sourced, dated, organized by name, and updated within 24 hours of any change we detect. We sell nothing. We just tell you where things actually stand.

Browse the atlasHow we track it
Compounds tracked
17
Last checked
today
Most recent status change
Semaglutide (compounded) - Apr 30, 2026

We automatically re-check the Federal Register, Regulations.gov and FDA compounding sources every day - 4 official sources - and update the moment a status moves.

Next FDA advisory committee: July 23, 2026, in 3 days. Seven peptides are up for review. We switch to hourly checks near the date.

See what's on the agenda →

The atlas

Grouped by U.S. status - most time-sensitive first. Tap any compound for the full picture.

Under review7Actively before the FDA advisory committee; a decision is pending and the status can move.

BPC-157

Under review

Body Protection Compound 157 · Bepecin · PL 14736

Not on the 503A Bulks List; before the FDA advisory committee Jul 23, 2026

Next Jul 23, 2026 · in 3 daysChanged Apr 16, 20262 primary sources

Emideltide (DSIP)

Under review

Delta sleep-inducing peptide · DSIP · Emideltide acetate

Removed from Category 2 (Apr 2026); not on the 503A list; before the FDA committee Jul 24, 2026

Next Jul 24, 2026 · in 4 daysChanged Apr 16, 20262 primary sources

Epitalon

Under review

Epithalon · Epithalone · AEDG

Removed from Category 2 (Apr 2026); not on the 503A list; before the FDA committee Jul 24, 2026

Next Jul 24, 2026 · in 4 daysChanged Apr 16, 20262 primary sources

KPV

Under review

Lysine-proline-valine · Lys-Pro-Val · KPV acetate

Removed from Category 2 (Apr 2026); not on the 503A list; before the FDA committee Jul 23, 2026

Next Jul 23, 2026 · in 3 daysChanged Apr 16, 20262 primary sources

MOTS-c

Under review

MOTs-C · Mitochondrial-derived peptide · MOTS-c acetate

Removed from Category 2 (Apr 2026); not on the 503A list; before the FDA committee Jul 23, 2026

Next Jul 23, 2026 · in 3 daysChanged Apr 16, 20262 primary sources

Semax

Under review

Semax acetate

No approved product; before the FDA committee Jul 24, 2026

Next Jul 24, 2026 · in 4 daysChanged Apr 16, 20261 primary source

TB-500 (Thymosin Beta-4)

Under review

TB-500 · Thymosin Beta-4 · TB-4

Removed from Category 2 in April 2026; now before the FDA committee, not on the 503A list

Next Jul 23, 2026 · in 3 daysChanged Apr 22, 20261 primary source
In limbo7Nominated or removed from a restricted list but NOT approved - the headline implies a change, but the legal reality did not move.

CJC-1295

In limbo

Modified GRF 1-29 · DAC:GRF · CJC-1295 DAC

PCAC voted against listing (Dec 2024); off Category 2, not on the 503A list

Changed Dec 4, 20242 primary sources

GHK-Cu

In limbo

Copper tripeptide-1 · Copper peptide · GHK-copper

Injectable removed from Category 2, not on the 503A list; PCAC review before Feb 2027

Next Feb 28, 2027 · in 223 daysChanged Apr 22, 20261 primary source

Ipamorelin

In limbo

Ipamorelin acetate

PCAC voted against listing (Oct 2024); off Category 2, not on the 503A list

Changed Oct 29, 20242 primary sources

Melanotan II

In limbo

MT-II · MT-2 · Melanotan-2

Off Category 2, not on the 503A list; PCAC review before Feb 2027

Next Feb 28, 2027 · in 223 daysChanged Apr 22, 20261 primary source

NAD+

In limbo

Nicotinamide adenine dinucleotide · NAD · β-NAD

Not on the finalized 503A list; no federal ban; compounded in a gray area

Changed Sep 5, 20192 primary sources

Selank

In limbo

Selank acetate · TP-7

Removed from Category 2 (2024); not on the 503A list; no scheduled review

Changed Sep 27, 20241 primary source

Thymosin Alpha-1

In limbo

Thymalfasin · Zadaxin · Tα1

Off Category 2, never in Category 1; PCAC declined Dec 2024

Changed Dec 4, 20243 primary sources
Restricted2Prescription-only, banned, controlled, or under active FDA enforcement.

Semaglutide (compounded)

Restricted

Ozempic · Wegovy · compounded semaglutide

Enforcement discretion ended; routine compounding no longer permitted

Next Jul 30, 2026 · in 10 daysChanged Apr 30, 20262 primary sources

Tirzepatide (compounded)

Restricted

Mounjaro · Zepbound · compounded tirzepatide

Enforcement discretion ended; broad compounding no longer permitted

Next Jul 30, 2026 · in 10 daysChanged Apr 30, 20262 primary sources
Compounding-legal1On the FDA 503A bulk-substances list; a licensed pharmacy may compound it. This is not the same as being an FDA-approved drug.

Sermorelin

Compounding-legal

GRF 1-29 · Geref · Sermorelin acetate

Category 1 of the interim 503A list - compoundable with a prescription

Changed Feb 19, 20191 primary source

The five states

We never reduce this to “legal / illegal.” Every badge pairs a color with a word, so status is readable without relying on color.

Under review
Actively before the FDA advisory committee; a decision is pending and the status can move.
In limbo
Nominated or removed from a restricted list but NOT approved - the headline implies a change, but the legal reality did not move.
Restricted
Prescription-only, banned, controlled, or under active FDA enforcement.
Compounding-legal
On the FDA 503A bulk-substances list; a licensed pharmacy may compound it. This is not the same as being an FDA-approved drug.
Unscheduled
No specific federal action; unaddressed at this time.

Who runs this - and why it stays neutral

Peptlas is maintained by the Peptlas Research Team, an independent group. We sell nothing - no products, no affiliates, no sponsors - so we have no stake in what any status turns out to be. Every entry links to its primary source and carries a human-verified date, and every change is logged in the open. About us · how we track it · the public record.

Informational only - not medical or legal advice, and no health claim. Always confirm against the linked primary source. Full disclaimer.